Introduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...
Read moreEMA has published Q&A document to prepare manufacturers for the UK's withdrawal from the EU with reg...
Read moreA one stop shop for joint advice between EMA, EUnetHTA and health technology assessment bodies - the...
Read moreIncluded in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...
Read moreMEAs are also known by other names such as risk-sharing agreements, value-added services, and result...
Read moreThe lack of a biosimilar market in the US is largely due to the substantial patent litigations which...
Read moreThis process aims to be completely transparent , to enable faster patient access to oncology treatme...
Read moreBoth payers and physicians do not believe that at the current prices Praluent and Repatha offer sign...
Read moreTopics covered include are payers helping or hindering biosimilar market access as well as can MCDA ...
Read moreMulti-criteria decision analysis (MCDA) is a potentially useful tool that can be used to support dec...
Read more